Stockreport

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report
PDF SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments [Read more]